Koichiro Ogihara, MD,PhD

Keio University School of Medicine

Presentation(s):

• MP01-02: Sulfasalazine could modulate the CD44v9-xCT system and enhance CDDP-induced cytotoxic effects in metastatic bladder cancer; A novel therapeutic strategy for metastatic bladder cancer

  Friday, May 15, 2020
  7:00 AM – 9:00 AM

• MP49-05: Pretreatment absolute monocyte count is a novel biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab

  Friday, May 15, 2020
  7:00 AM – 9:00 AM